Literature DB >> 11719729

Stereoselective pharmacokinetics of ketamine: R(-)-ketamine inhibits the elimination of S(+)-ketamine.

H Ihmsen1, G Geisslinger, J Schüttler.   

Abstract

OBJECTIVE: We investigated the pharmacokinetics of ketamine with special regard to enantiomer-specific differences.
METHODS: Ten healthy young male volunteers (mean age, 28 +/- 4 years; mean weight, 79 +/- 11 kg) received racemic ketamine and S(+)-ketamine in a randomized double-blind crossover study. Drugs were administered by a computer-controlled device. Two infusion cycles with linearly increasing targets [slope, 0.1 microg x ml(-1) x min(-1) for S(+)-ketamine and 0.2 microg x ml(-1) x min(-1) for racemic ketamine] were administered. Concentrations of the ketamine enantiomers were determined from arterial blood, and pharmacokinetic parameters were estimated with a 2- and 3-compartment model.
RESULTS: The total doses needed to reach defined end points were 271 +/- 80 mg and 409 +/- 75 mg for S(+)-ketamine and racemic ketamine, respectively (P <.05). S(+)-ketamine showed a significantly higher clearance (26.3 +/- 3.5 ml x kg(-1) x min(-1)) compared with racemic ketamine (14.8 +/- 1.7 ml x kg(-1) x min(-1); P <.05) and R(-)-ketamine (13.8 +/- 1.3 ml x kg(-1) x min(-1); P <.05). Furthermore, the clearance of the S (+)-ketamine was smaller in the racemate (18.5 +/- 0.7 ml x kg(-1) x min(-1); P <.05) than for the pure isomer.
CONCLUSIONS: These results demonstrate that R(-)-ketamine inhibits the elimination of S(+)-ketamine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11719729     DOI: 10.1067/mcp.2001.119722

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  22 in total

1.  Pharmacodynamic profiles of ketamine (R)- and (S)- with 5-day inpatient infusion for the treatment of complex regional pain syndrome.

Authors:  Michael E Goldberg; Marc C Torjman; Robert J Schwartzman; Donald E Mager; Irving W Wainer
Journal:  Pain Physician       Date:  2010 Jul-Aug       Impact factor: 4.965

2.  Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing.

Authors:  Samuel Fanta; Mari Kinnunen; Janne T Backman; Eija Kalso
Journal:  Eur J Clin Pharmacol       Date:  2015-03-01       Impact factor: 2.953

3.  A parallel chiral-achiral liquid chromatographic method for the determination of the stereoisomers of ketamine and ketamine metabolites in the plasma and urine of patients with complex regional pain syndrome.

Authors:  Ruin Moaddel; Swarajya Lakshmi Vattem Venkata; Mary J Tanga; James E Bupp; Carol E Green; Lalitha Iyer; Anna Furimsky; Michael E Goldberg; Marc C Torjman; Irving W Wainer
Journal:  Talanta       Date:  2010-08-13       Impact factor: 6.057

4.  Pharmacokinetic-pharmacodynamic modelling of ketamine in six neurotraumatised intensive care patients.

Authors:  Youssef Hijazi; Carole Bodonian; François Salord; Françoise Bressolle; Roselyne Boulieu
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

5.  Pharmacokinetics of Ketamine at Dissociative Doses in an Adult Patient With Refractory Status Asthmaticus Receiving Extracorporeal Membrane Oxygenation Therapy.

Authors:  Edwin Lam; Ankit Rochani; Gagan Kaushal; Brandi N Thoma; Julian Tanjuakio; Frances Mae West; Hitoshi Hirose
Journal:  Clin Ther       Date:  2019-03-28       Impact factor: 3.393

6.  Antinociceptive effects, metabolism and disposition of ketamine in ponies under target-controlled drug infusion.

Authors:  M Knobloch; C J Portier; O L Levionnois; R Theurillat; W Thormann; C Spadavecchia; M Mevissen
Journal:  Toxicol Appl Pharmacol       Date:  2006-07-03       Impact factor: 4.219

Review 7.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 8.  Advances in translational neuropathic research: example of enantioselective pharmacokinetic-pharmacodynamic modeling of ketamine-induced pain relief in complex regional pain syndrome.

Authors:  Michael Sabia; Robert A Hirsh; Marc C Torjman; Irving W Wainer; Niti Cooper; Richard Domsky; Michael E Goldberg
Journal:  Curr Pain Headache Rep       Date:  2011-06

9.  Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression.

Authors:  Xiaochen Zhao; Swarajya Lakshmi Vattem Venkata; Ruin Moaddel; Dave A Luckenbaugh; Nancy E Brutsche; Lobna Ibrahim; Carlos A Zarate; Donald E Mager; Irving W Wainer
Journal:  Br J Clin Pharmacol       Date:  2012-08       Impact factor: 4.335

Review 10.  Expanding Role of NMDA Receptor Antagonists in the Management of Pain.

Authors:  Denise Kreutzwiser; Qutaiba A Tawfic
Journal:  CNS Drugs       Date:  2019-04       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.